Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2002

View Archived Issues

New nonsteroidal therapy for atopic eczema effective in over two-thirds of adults

Erythromelalgia: the story so far

Immunomodulation with ciclosporin complements HAART as a treatment for HIV infection

Enoxaparin as adjunctive antithrombin therapy significantly superior to unfractionated heparin

Two licensing opportunities from NIH

SRF2, a TGF-beta antagonist, available for licensing from NIH

Zevalin advances to clinical trials in Japan

BMP-7 effectively preserves or restores renal histology and function in animal model

Sustained seroconversion reported in 24% of Japanese hepatitis B patients on Zadaxin

Early access program initiated for Gilead's adefovir dipivoxil in chronic HBV

GeneData and AstraZeneca collaborate on antiinfective genomics research

AxCell collaborates with Mount Sinai on muscular dystrophy research

Ricerca inlicenses RAP-3 gene for oncology drug discovery

Genmab and Bionomics collaborate on human antibody development for angiogenesis targets

Nuvion enters phase II trial in steroid-refractory graft-versus-host disease

Forest terminates agreement with Merckle for ML-3000

FDA issues complete review letter for Bexxar, requests further clinical studies

Corvas and Schering-Plough describe new HCV protease inhibitors

Coley and Aventis expand asthma and allergic rhinitis collaboration

Kineret approved in E.U. for RA

Merck scientists report novel compounds for anxiety

Derivatives with antitumor activity identified at Zentaris

Compounds for sexual disorders reported by Lilly Icos

SLIL claims potential new treatments for prostate cancer

Novel potassium channel openers described in a recent patent from Abbott

Sigma-Tau designs atypical antipsychotic agents with an improved profile

Dual MAO-A/MAO-B inhibitor better than selective inhibitors in improving parkinsonian symptoms

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...